Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Bonn Neuroscientists Participating in International Initiative for Study of Rare Diseases

03.12.2012
Scientists from the German Center for Neurodegenerative Diseases (DZNE) are participating in an international research project on the causes of rare degenerative brain and muscle disorders.

Over the next five years, the DNZE Bonn site will receive 470,000 euros for the effort. The project, entitled "NEUROMICS: Integrated European Project on Omics Research of Rare Neuromuscular and Neurodegenerative Diseases," is being funded under the EU's Seventh Framework Programme for Research.

The partners in the effort hail from Europe, Australia, Canada and the United States.

"Such a concerted effort on this scale is unprecedented," explains Prof. Thomas Klockgether, Director of Clinical Research at the DZNE. Relevant work in Bonn will focus on patients and healthy people with increased risks of disease. "We expect the work to yield new findings on the causes of such diseases and to provide impetus for diagnosis and therapy," notes Klockgether.

NEUROMICS is focused on a range of brain and movement disorders that are classified as "rare." That classification notwithstanding, in Europe alone the group of those affected – with symptoms including paralysis, muscle tremors, memory loss and dementia – amounts to more than half a million people. To date, only a limited range of therapies is available for easing these rare "neurodegenerative" and "neuromuscular" disorders. And little research has been conducted into the causes of such disorders. "Fortunately, the various disorders overlap in many areas, and virtually the same methods are always used to study them," Klockgether explains. "It thus makes a great deal of sense to tackle these diseases in the context of a single project."

A disease is considered "rare" when it affects fewer than five out of every ten thousand people. It is estimated that there are 6,000 to 8,000 such diseases. NEUROMICS is focusing on a total of ten of them: diseases such as Chorea Huntington, which involves motor and mental disorders, and the group of muscular dystrophies, which lead to muscle atrophy. "Several factors led to this selection," Klockgether reveals. "On the one hand, the diseases needed to be representative, i.e. to have a certain prevalence. On the other hand, the studies involved are only possible on the basis of long experience and a certain type of infrastructure, which is only available for certain diseases." The potential for including existing groups of patients within the studies is of central importance. "A relevant group of people has to be available. It can't simply be built on an ad hoc basis," emphasizes Klockgether.
The emphasis in Bonn: movement disorders

In NEUROMICS, DZNE researchers will be contributing expertise especially in the area of "ataxia". Ataxia sufferers have reduced muscle control, and they are prone to balance loss, incoordination and speech disorders. Such impairments are triggered by brain and spinal damage that can result from many different types of diseases. Klockgether, who is also head of the University of Bonn's Center for Rare Diseases, and his team are currently treating several hundred such patients.

One aspect of NEUROMICS includes studying persons who, while showing no symptoms, have an increased risk of disease as a result of their genetic disposition. "Such an increased risk may be found in close relatives of patients," explains Klockgether. "We are thus hoping that relatives of our patients will agree to take part in the studies."

Diversity of methods

Neurological disorders develop over long periods of time. Therefore noticeable findings can be made years before a disease makes an obvious appearance, Klockgether explains. "We are thus planning to study healthy persons with an increased risk of disease as comprehensively as possible." To carry out those plans, the researchers in Bonn will use a variety of different procedures, including magnetic resonance imaging (MRI) – which provides detailed views of the brain's interior – and tests of motor and cognitive skills.

In addition, blood samples will be taken from the persons being studied in Bonn and then analyzed by project partners, in the framework of the international cooperation for the effort. Those studies will make use of state-of-the-art technologies for gene and protein analysis. Such technologies are collectively referred to as "omics technologies" – as is reflected in the project name, NEUROMICS.
The technologies are expected to help identify "biomarkers". Biomarkers are indicators - found in blood tests results, genomic analysis or MRI scans (for example) - that can identify a disease before the first symptoms appear. Needless to say, biomarkers play a highly significant role in early detection.

Klockgether and his colleagues also plan to study underlying causes: "A number of these rare diseases are known to be inheritable," he notes. "At the same time, we are not aware of all of the genes involved in such inheritance. The specific objectives of NEUROMICS include finding such genes and thereby improving our understanding of the molecular triggers behind these diseases. This work may produce new approaches for therapies."

For further information: http://www.rd-neuromics.eu
The German Center for Neurodegenerative Diseases (DZNE) studies the causes of diseases of the nervous system and develops strategies for relevant prevention, therapy and care. An institution within the Helmholtz Association of German Research Centres, it has sites in Berlin, Bonn, Dresden, Göttingen, Magdeburg, Munich, Rostock/Greifswald, Tübingen and Witten. The DZNE cooperates closely with universities, their clinics and other research facilities. Website: http://www.dzne.de/en

Dr. Marcus Neitzert | idw
Further information:
http://www.dzne.de/en
http://www.rd-neuromics.eu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>